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Abstract
 .The level of various G1 cyclins and cyclin-dependent kinases cdks present in the nuclei of synchronized ML-1 human
myeloblastic leukemia cells was determined as a function of time after initiation of cell growth with insulin-like growth
 .  .factor-1 IGF-1 and transferrin Tf , and following induction of differentiation with transforming growth factor-b1
 .TGF-b1 . Cyclin E and cdk2 were expressed at relatively high levels in the nuclei of proliferation-stimulated cells,
whereas cyclin D1 and cdk5 were expressed at comparably high levels in the nuclei of differentiation-induced cells. In the
nuclear extracts from proliferation-stimulated cells, cyclin E complexed specifically with cdk2, whereas in nuclear extracts
from differentiation-induced cells, cyclin D1 bound specifically to cdk5. Increased cyclin Ercdk2 expression was
accompanied by increased DNA synthesis, whereas increased cyclin D1rcdk5 levels correlated with decreased DNA
synthesis. In both growth- and differentiation-induced cells, cyclin D2 expression preceded the expression of cyclin D3, and
a significantly larger amount of these cyclins was present in differentiation- as compared to proliferation-induced cells. In
contrast, cdk4 and cdk6 were present at similar levels in the nuclear extracts from both growth- and differentiation-induced
cells. These data show that, in ML-1 cells, the proliferation-associated progression from G1 to S, as well as the
differentiation-associated transit from G1 to maturation is accompanied by the expression of specific cyclinrcdk pairs,
comprising cdk2rcyclin E in growth and cdk5rcyclin D1 in differentiation.
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1. Introduction
It is, by now, well established that cyclins, in
association with cdks, function as regulators of prolif-
w xeration-related cell cycle progression 1 . However,
only limited information has become available on the
role these proteins may play in regulating the exit
from the cell cycle onto the differentiation path. As
one approach towards obtaining further such informa-
tion, we compared cyclinrcdk expression in cells
grown under proliferation- and under differentiation-
specific conditions. Since both growth- and differen-
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tiation-inducing cytokines are present in the sera
generally used for cell culturing, an assay system was
required wherein serum is depleted in favor of spe-
cific cytokines.
The system we used consisted of ML-1 human
w xmyeloblastic leukemia cells 2 which, in the absence
of serum, proliferate in RPMI 1640 medium when
IGF-1 and Tf are supplied, or differentiate to mono-
cytes when TGF-b1 andror tumor necrosis factor-a
 .TNF-a are furnished in the presence of Tf. In
 .long-term cultures )48 h , the addition of 0.5%
fetal calf serum to the medium maintains cell viabil-
ity at above 80%, without significantly affecting the
extent of growth or differentiation. Because different
regulatory proteins are expressed or activated at dif-
ferent stages in the cell cycle for an overview see for
w x.example 3 , determining the type and level of such
proteins present at diverse stages of the cell cycle
requires the use of synchronized cell populations.
Staging assures that any differences detected reflect
the conditions that exist in the total cell population
rather than in fractions of the population present at
different stages of the cell cycle.
Additionally, because the cytoplasmic fraction
contains differentially phosphorylated cdks and cy-
clins as well as auxiliary binding proteins that assume
nuclear functions only during specific cell cycle
w xphases 4–6 , utilizing total cell extracts can lead to
erroneous conclusions. We, therefore, focused our
inquiry on determining the type and level of cyclins
and cdks expressed in the nucleus of ML-1 cells at
specific time points following induction of growth or
differentiation. In so doing, we expected to obtain
information concerning the regulatory proteins most
immediately involved in the control of cell cycle
progression.
A preliminary report on part of this work has been
w xpresented 7 .
2. Materials and methods
2.1. Cytokines and antibodies
TGF-b1 was kindly provided by Bristol-Myers
Squibb, Seattle, WA., and IGF-1 was purchased from
Austral Biologicals, San Ramon, CA. The following
antibodies were obtained from Santa Cruz Biotech-
nology: HD11, a mouse IgG monoclonal antibody1
derived by fusion of NSr1 mouse myeloma cells
with spleen cells from a mouse immunized with
recombinant human cyclin D1. PRAD1, a rabbit
polyclonal antibody raised against a peptide corre-
sponding to amino acids 9–37 of the human cyclin
w xD1 gene product 8–10 . C-17, a rabbit polyclonal
antibody targeted to a peptide containing the human
w xcyclin D2 amino acid residues 274–290 10 . The
antibody is characterized as not being reactive with
either cyclin D1 or cyclin D3. Antibody 34B1-3, a rat
IgG monoclonal antibody, derived by fusion of rat2a
myeloma cells with spleen cells from a rat immu-
nized with recombinant human cyclin D2. The anti-
body is specified to lack detectable cross-reactivity
with either cyclin D1 or D3. Antibody 18B6-10, a rat
IgG monoclonal antibody derived by fusion of rat2a
myeloma cells with spleen cells from a rat immu-
nized with recombinant human cyclin D3. It is stated
to lack detectable cross-reactivity with either cyclin
w xD1 or D2 10–13 . C-16, an affinity-purified rabbit
polyclonal antibody raised against the peptide con-
taining amino acid residues 277–292 of human cyclin
w xD3 10,12 . That antibody is represented as being
non-cross-reactive with either cyclin D1 or D2. Cy-
clin E was detected with antibody HE12 and C-19.
HE12 is a mouse IgG monoclonal antibody derived2b
by fusion of NSr1 mouse cells with spleen cells
from a mouse immunized with recombinant human
cyclin E protein, whereas C19 is a rabbit polyclonal
antibody raised to a peptide incorporating the human
w xcyclin E amino acid residues 377–395 14,15 . The
cdk5-directed antibody DC-17, used in this study, is a
mouse IgG monoclonal antibody, derived by fusion1
of NSr1 mouse cells with spleen cells from a mouse
immunized with human recombinant cdk5 protein
w x16 . Another cdk5-directed antibody used, C-8, is a
rabbit polyclonal antibody raised against the peptide
containing the amino acid residues 284–291 mapping
w xat the carboxy terminus of cdk5 17,18 . Cdk2 was
detected by antibody M2, a rabbit polyclonal anti-
body raised to a peptide containing the amino acids
283–298 mapping at the carboxy terminus of human
w xcdk2 15,17,19 . Antibody C-22 is a rabbit polyclonal
antibody raised against a peptide containing the
residues 282–303 that map at the carboxy terminus
 . w xof of human cdk4 p34 psk-J3p34 17,18 . The anti-
body is stated to be not cross-reactive with other
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cyclin-dependent kinases. Similarly, C-21, a rabbit
polyclonal antibody raised against a peptide corre-
sponding to amino acid residues 303–326 mapping at
 . w xthe carboxy terminus of cdk6 PLSTIRE 17,20 , is
characterized as being non cross-reactive with other
cdks. A cyclin D2-directed rat monoclonal antibody
 .Ab-1 , purchased from Oncogene Science, Inc.,
Cambridge, MA, was also used in this study.
2.2. Reagents
Goat anti-mouse, goat anti-rat and goat anti-rabbit
IgG were purchased from Santa Cruz Biotechnology;
and immobilized protein A from Pierce, Rockford,
IL. Molecular standards, used in sodium dodecil sul-
 .fate polyacrylamide gel electrophoresis SDS-PAGE ,
were obtained from Bio-Rad Labs., Hercules, CA and
western blotting reagents were purchased from Amer-
sham International, Arlington Heights, IL.
2.3. Cell cultures
Suspension cultures of ML-1 human myeloblastic
leukemia cells were maintained in RPMI 1640
medium supplemented with 10% heat-inactivated fe-
 .tal bovine serum FBS 100 unitsrml of penicillin
w xand 100 mgrml of streptomycin 2 . The cells were
incubated at 378C, in a humidified 5% CO atmo-2
sphere. For assessing the expression of cell cycle-reg-
ulating proteins, 6–7=105 cellsrml were removed
from the maintenance culture, washed with RPMI
1640 medium and synchronized by incubation for 2
days at 378C in RPMI 1640 medium containing
0.05% FBS. Following this staging, from 80–85% of
the cells were in G1. After washing twice with
serum-free RPMI 1640 medium, the cells were resus-
pended in RPMI 1640 medium containing 0.5% FBS
and were treated with 40 ngrml IGF-1 plus 0.5
mgrml transferrin for growth, or with 60 ngrml of
TGF-b1 plus 0.5 mgrml TF for differentiation. The
0.5% serum supplement was added to preserve the
viability of the cultures over the 72 h incubation
period employed. Cell numbers were determined by
hemocytometer, viability was assessed by trypan blue
exclusion, and differentiation monitored by counting
the number of cells displaying differentiated mor-
w xphology 2 .
2.4. Nuclear extracts
To obtain nuclear extracts, 2–5=107 cells were
washed with serum-free, ice-cold RPMI 1640
medium, followed by suspension in 0.3 ml of a
nuclear buffer consisting of 2 mM MgCl , 5 mM2
K HPO , 0.1 mM ethylenediaminetetraacetic acid2 4
 .EDTA , 1 mM phenylmethylsulfonylfluoride
 .PMSF , 20 mgrml aprotinin, 20 mgrml leupeptin
and 0.1 mM Na VO . An additional 0.3 ml of nuclear3 4
buffer, containing 0.7% of Triton X-100, was then
added and, after standing on ice for 8 min, the cells
were homogenized using a Dounce tissue grinder,
and the homogenate centrifuged at 150=g. The pel-
let was washed once with nuclear buffer and the
nuclear extract prepared using the method of Dignam
w xet al. 21 . Briefly, the pellet was resuspended in
buffer containing 20 mM N-2-hydroxyethylpipera-
X  .zine-N -2-ethanesulfonic acid Hepes , pH 7.9, 25%
glycerol, 0.42 M NaCl, 1.5 mM MgCl , 0.2 mM2
 .EDTA, 0.5 mM PMSF, 0.5 mM dithiothreitol DTT ,
0.1 mM Na VO , 50 mM NaF, 30 mM pyrophos-3 4
phate, 20 mgrml leupeptin and 20 mgrml aprotinin,
and homogenization was carried out using a Kontes
 .Duall tissue grinder. After centrifugation 12 000=g
of the homogenate, the supernatant, designated the
nuclear extract, was frozen and stored at y708C.
2.5. Western blotting
The cyclin and cdk proteins were analysed by
western blotting. Fractions containing 30–50 mg of
nuclear protein were loaded onto 10% polyacryl-
amide SDS gel, and after electrophoresis in discontin-
uous buffer, the proteins were transferred to nitro-
cellulose membranes using a trans-blot elec-
trophoretic transfer cell. The membranes were blocked
for 2 h with 5% milk in phosphate buffered saline
 .PBS , followed by incubation with primary antibody
for 1–2 h. After washing once for 15 min and three
times for 5 min with PBS containg 0.1% Tween 20,
the membranes were incubated with secondary anti-
body for 40–60 min, washed, and incubated for 1
minute in Amersham ECL reagent. Kodak x-omat
AR or Dupont NEN films were used for autoradiog-
raphy. Developed films were scanned by computing
densitometer, and relative levels determined by refer-
ence to the stated controls.
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2.6. Immunoprecipitation and immunoblotting
Immunoprecipitation was performed by established
w xprocedures. 15,18,22 . Briefly, excess nuclear extract
 .200 mg protein from synchronized ML-1 cells incu-
bated in the absence or presence of IGF-1 or TGF-b1
was added to 300 ml of immunoprecipitation buffer
containing 50 mM Tris-HCl, pH 7.4, 250 mM NaCl,
0.5% NP-40, 20 mM EDTA, 0.1 mM Na VO , 503 4
mM NaF, 1 mM PMSF, 1 mM benzamidine, 10
mgrml trypsin inhibitor, 20 mgrml leupeptin and 20
mgrml aprotinin. To each sample, 1mg of affinity-
purified antibody was added in the presence or ab-
sence of peptide controls. After rocking at 48C for
1–2 h, immobilized protein A was added to each
sample, and rocking continued overnight. Immuno-
precipitates were collected by Microfuge centrifuga-
tion, and after washing four times with 1 ml aliquots
of immunoprecipitation buffer, the pellets were resus-
w xpended in 40 ml aliquots of sample buffer 23 . After
boiling for 3 min, the proteins were separated on 10%
SDS-PAGE, transferred to nitrocellulose membranes
and detected by ECL as described above.
[3 ]2.7. H thymidine incorporation
5=105 synchronized ML-1 cellsrml were treated
for the indicated periods of time with the amounts of
growth or differentiation factors specified. 1 h before
w3 x harvest, H thymidine 1 mCirml; specific activity
.87 Cirmmol was added to each culture, and incuba-
tion continued for an additional h. The cells were
collected by centrifugation at 200=g, and 1 ml of
 .10% trichloroacetic acid TCA was added to the
pellet. After resuspension, the cells were collected on
glass microfiber filters, washed with 5%
TCArethanol, and the radioactivity present on the
dried filters determined by scintillation spectrometer.
3. Results
As shown in Fig. 1a, synchronized ML-1 cells
stimulated to proliferate with IGF-1 plus Tf, under-
went division between 60–70 h of incubation. A
small increase in cell number was also observed in
the control population which, like all assay samples,
was cultured in the presence of 0.5% fetal calf serum,
added to maintain cell viability at above 80% during
the 72 h incubation period. The small amount of
growth factor present in the serum suffices to stimu-
late the growth of this small fraction of cells, as is
indicated by the fact that no such increase in cell
number occurred in the cell population treated with
the differentiation-factor TGF-b1, the elevated level
 .  .Fig. 1. a Total cell number and b percent of differentiated cells obtained after incubating, at 378C, a population of synchronized ML-1
cells suspended in RPMI 1640 medium containing 0.5% FBS and 40 ngrml IGF-1 or 60 ngrml TGF-b1 together with 0.5 mgrml
transferrin. Cell numbers were counted by hemocytometer and the percent of differentiated monocytes determined on the basis of
morphology. The data shown are the mean"SD derived from three separate experiments, at least 500 cells being scored in each
experiment.
( )Z.-r. Li et al.rBiochimica et Biophysica Acta 1356 1997 149–159 153
of differentiation factor antagonizing the low level of
w xgrowth signal that is present 24 .
As shown in Fig. 1b, approximately 80% of the
cell population treated with TGF-b 1 matured to
monocytes, whereas only a small fraction approxi-
.mately 8% of the cells matured in control and an
 .  .  .  .Fig. 2. Levels of cdk2 a , cyclin E b , cdk5 c and cyclin D1 d proteins present in nuclear extracts from synchronized ML-1 cells
incubated, at 378C, in RPMI 1640 medium containing 0.5% FBS, 40 ngrml of the growth factor IGF-1, or 60 ngrml of the
differentiation factor TGF-b1 and 0.5 mgrml transferrin. Aliquots of the nuclear extracts, containing 30 mg protein, were immuno-
blotted, and the blots probed with monoclonal or with affinity-purified polyclonal antibodies. Cells incubated in the absence of IGF-1 or
TGF-b1 served as control. All values obtained were normalized to the 6 h control value, which was set equal to 1. The 6 h control value
did not differ significantly from the value at 0 time. The data shown are means"SD derived from three separate experiments.
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 .even smaller number 2% in the IGF-1-treated cul-
tures. The small difference between control and the
IGF1-treated culture is real, reflecting the competi-
tion that exists between the elevated level of IGF-1
added to the proliferation- stimulated culture and the
small amount of differentiation factor that is con-
w xtained in the 0.5% amount of serum supplied 24 .
To obtain information on the possible role cell
cycle regulating proteins may play in directing prolif-
erating cells towards the differentiation path, we
compared the identity and the level of the cyclins and
cdks present in the nuclei from proliferation- and
from differentiation-induced ML-1 cells.
The transition from the G1 phase of the cell cycle
to the S phase constitutes a well characterized locus
for regulating the cycle progression of proliferating
cells. That transit has been demonstrated to involve
w xthe cdk2rcyclin E pair 14,25,26 . As shown in Fig.
2a, the level of cdk2 present in the nuclei of prolifera-
tion-stimulated ML-1 cells increased approx. 10-fold
after 46 h of incubation and declined slowly there-
after. A small increase in cdk2 level was also ob-
served in control cells, that increase likely reflecting
the small amount of IGF-1 present in the 0.5% serum
supplement that was added. In contrast, in the matu-
w3 xFig. 3. DNA synthesis, as determined by H thymidine incorpo-
ration, in synchronized ML-1 cells incubated, at 378C, in serum-
depleted medium containing the growth factor IGF-1 or the
differentiation factor TGF-b1. The amount of thymidine incorpo-
rated is given relative to 0 h control. The values shown represent
the mean"SD of three separate experiments.
Fig. 4. Complexation of cdk2 with cyclin E, and of cdk5 with
cyclin D1, in nuclear extracts from synchronized ML-1 cells
 .  .incubated for 46 h A or for 40 h B in RPMI 1640 medium
supplemented with 0.5% FBS and with 40 ngrml of the growth
factor IGF-1 or with 60 ngrml of the differentiation factor
TGF-b1, together with 0.5 mgrml of transferrin. Nuclear ex-
 .tracts 200 mg protein from these cells were immunoprecipitated
 .  .with aliquots 1 mg protein of anti-cdk2 A, a, c , anti-cyclin E
 .  .  .A, b, d , anti-cdk5 B, a, c , or anti-cyclin D1 B, b, d
antibodies. Following immunoprecipitation, the precipitates were
 .probed with antibodies to cdk2 and cyclin E A , and with
 .  .antibodies to cdk5 and cyclin D1 B . In A , control peptides for
cdk2 or for cyclin E were added to the IGF-1- treated immuno-
 .precipitates, whereas in B , control peptides for cdk5 or for
cyclin D1 were added to the TGF-b1-treated immunoprecipi-
tates.
ration stimulated cells, no significant elevation of the
cdk2 level was observed at that time interval.
 .In parallel with cdk2 Fig. 2a , cyclin E, the
regulatory subunit of cdk2, was maximally expressed
at the same time point at which cdk2 reached its
 .optimal level Fig. 2b . However, while the cdk2
level declined slowly, the level of cyclin E decreased
much more rapidly, in keeping with the notion that
the cyclins regulate the activity of their target cdks.
In control and in differentiation-induced cells, the
cyclin E levels increased only marginally.
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Whereas the cdk 2rcyclin E levels were elevated
in the nuclei of proliferation-stimulated cells Fig.
.2a,b , it was the cdk5rcyclin D1 levels that were
increased in the nuclei of differentiation-induced cells
 .Fig. 2c,d .
The kinetics of cdk5 expression in the maturation-
 .induced cells Fig. 2c differed significantly from the
kinetics with which cdk2 was expressed in proliferat-
 .ing cells Fig. 2a . The maximal level of cdk5 was
reached after about 35 h of incubation, whereas cdk2
expression reached its optimal level after approxi-
mately 46 h. Further, while elevated cdk5 levels were
maintained over the remainder of the 72 h incubation
 .period Fig. 2c , the cdk2 levels began to decrease
 .soon after reaching their maximum Fig. 2a . Analo-
gously, while the cyclin D1 level remained elevated
 .upon incubation past 35 h Fig. 2d , the cyclin E
level decreased sharply following the 46 h time point
 .Fig. 2b . That difference may reflect the fact that the
cdk2rcyclin E complex regulates a transient but
recurring event involving the transition of the cells
from G1 to the S-phase, whereas the cdk5rcyclin D1
complex appears to be involved in a more permanent
event related to the non-recurring expression of the
differentiation program.
That interpretation receives support from the data
shown in Fig. 3. In proliferation-stimulated cells,
maximal cdk2rcyclin E expression coincides with
maximal DNA synthesis required for cell division,
whereas, in differentiation-induced cells, optimal ex-
pression of cdk5rcyclin D1 is associated with the
loss of that synthesis, expected from cells that are
slated to move towards functional maturity rather
than towards division.
To assess whether the simultaneous increase in the
levels of cdk2 and cyclin E in growing cells, and of
cdk5 and cyclin D1 in differentiating cells is paral-
leled by the ability of these proteins to bind, immuno-
precipitates generated in nuclear extracts from growth-
or from differentiation-induced cells were probed for
their constituent proteins. As shown in Fig. 4A, b and
c, complexation between cdk2 and cyclin E occurred
only in nuclear extracts from proliferation-stimulated
cells, even though small amounts of these two pro-
teins were also present in nuclear extracts from con-
trol and from differentiation-induced cells Fig. 4A, a
Fig. 5. Changes in the levels of cdk4 and cdk6 proteins in nuclear extracts from synchronized ML-1 cells incubated, at 378C, in RPMI
1640 medium containing 0.5% FBS and 40 ngrml of the growth factor IGF-1 or 60 ngrml of the differentiation factor TGF-b1. The
extracts were subjected to immunoblotting, and the blots probed with polyclonal antibodies to cdk4 and cdk6. Cells incubated in the
absence of either IGF-1 or TGF-b1 served as control. All values obtained were normalized to the 6 h control value. Each experimental
point represents the mean"SD derived from three separate experiments.
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Fig. 6. Cyclin D2 and D3 levels present in nuclear extracts from synchronized ML-1 cells, cultured in RPMI 1640 medium plus 0.5%
FBS in the presence of 40 ngrml of the growth-factor IGF-1 or 60 ngrml of the differentiation factor TGF-b1. The extracts were
immunoblotted and the blots probed with monoclonal or with polyclonal antibodies to the cyclins D2 and D3. Cells incubated in the
absence of either cytokine served as control. All values obtained were normalized to the 6 h control value. Each experimental point
represents the mean"SD derived from three separate experiments.
.and d . This result implies that, in the proliferation-
stimulated cells, these two proteins may have under-
gone some modification that promotes complex for-
 .mation e.g. phosphorylation , or indicates that auxil-
iary binding proteins required for complexation were
present.
Analogously, complexation of cdk5 with cyclin D1
occurred predominantly in nuclear extracts from dif-
 .ferentiation-induced cells Fig. 4B, b and c , even
though small concentrations of these proteins were
present in control and in proliferation-stimulated cells
 .Fig. 4B a and d . No significant complex formation
between cdk5 and the D2 or D3 cyclins was observed
 .data not shown .
In contrast to cdk2, expressed at a relatively high
concentration in growth, and cdk5, expressed at an
elevated level in differentiation, the cdks 4 and 6
were present at similar levels in the nuclei of control
as well as of proliferation- and differentiation-in-
 .duced cells Fig. 5 . This similiarity may mean that
they affect cellular activities that are common to
control as well as to proliferating and differentiating
cells. Under conditions where cyclin D1 was bound
to cdk5, no significant binding of cyclin D1 to cdk4
 .or cdk6 was observed data not shown .
Similarly, as shown in Fig. 6, the D2 and D3
cyclins were expressed in both growth and differenti-
ation-induced cells relatively early in G1. Cyclin D2
reached its peak level after approximately 18 h,
whereas cyclin D3 reached that level after approx. 22
h of incubation. Both cyclins were expressed at sig-
nificantly greater levels in differentiation- than in
proliferation-induced cells or in control, but the time
point at which they were maximally expressed was
the same in all instances.
4. Discussion
The orderly progression of a cell through its prolif-
eration cycle is linked to the sequential activation of
several cyclinrcdk complexes that assure the proper
integration of the multitude of cellular activities re-
w xquired for error-free cell division 1 . By their ability
to phosphorylate specific substrates, these complexes
regulate the expression of cycle-specific genes. Dif-
ferent cyclinrcdk pairs are utilized for regulating
specific stages of the cell cycle, and their level of
expression, the extent of their phosphorylation and
the presence of negative regulatory proteins, all deter-
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mine the kinase activity that results. The determinant
role this activity plays in cell proliferation has been
documented in an enormous number of publications,
and only a very few of the most recent reviews can
w xbe referenced here 3,27–29 .
Unlike the massive amount of data pertaining to
the role cyclinrcdk complexes play in regulating
growth, relatively little information has been accrued
concerning the functions they may serve in differenti-
ation.
The study reported here indicates that at least one
specific cyclinrcdk pair is involved in cellular events
related to the transit from growth to differentiation.
While the regulatory action of the cyclin Ercdk2 pair
in the G1rS phase transition has been well docu-
w xmented 30 , the differentiation-associated expression
of the cyclin D1rcdk5 pair has not previously been
described.
Cyclin Ercdk2 complexes have been observed to
associate with transcription factors such as E2F, which
act at promoters of genes encoding proteins required
w xfor DNA replication and growth 15,31–33 . By anal-
ogy, the cyclin D1rcdk 5 complex may interact with
factors which promote the expression of the stable
messages suggested to be associated with differentia-
w xtion-related gene expression 34 . Whatever the case,
the simultaneous expression of these two complexes
appears incompatible with progression towards
growth or differentiation. Thus, down-regulation of
the cdk2 or cyclin E levels appears crucial for PC12
w xcells to undergo neuronal differentiation 35 , whereas
down-regulation of cyclin D1 is required for human
w xfibroblasts to initiate DNA replication and repair 36 .
Since initiation of ML-1 cell differentiation by
TGF-b1 is accompanied by the down-regulation of
 .cdk2rcyclin E levels Fig. 2a, b followed by growth
 .arrest Fig. 1 , it was of interest to note that TGF-b1
can affect cdk2-cyclin E activity in other cell types as
well. Thus, TGF-b1 was shown to block cyclin E
w xexpression in human keratinocytes 37 and, in Mv1Lu
cells, this cytokine inhibited the assembly of the
w xcyclin Ercdk2 complex 38 . The growth inhibitory
effect exerted by TGF-b1 on keratinocytes involved
the enhanced binding of p21rCip1rWaf1 to cdk2
w x39 , whereas the inhibition of complex formation in
w xMv1Lu cells 38 was mediated through the increased
binding of p27Kip1 to cdk2. A TGF-b1-induced
increase in the level of p21rCip1rWaf1 was ob-
served in two colon cancer cell lines, where binding
of this protein to cyclin E resulted in reduced cyclin
w xE activity 40 . Additionally, TGF-b1 was found to
interfere with cdk2 phosphorylation in late G1, pre-
venting, thereby, the activation of its histone kinase
w xactivity 41 .
Thus, TGF-b1 interferes with cyclin Ercdk2 for-
mation and growth not only in ML-1, but also in
diverse other cell types, and it remains to be estab-
lished whether in such cells -as is the case in ML-1-
the cyclin D1rcdk5 pair is expressed preliminary to
the induction of differentiation. Indeed, the level of
cdk5 as well as of cyclin D1 was found to be
increased during the differentiation of various other
cell types. Thus, cdk5 levels and activity increased in
embryonic mouse forebrain as increasing numbers of
cells exited proliferation, whereas cdk2 expression
and activity was maximal when the majority of cells
were proliferating and fell to barely detectable levels
w xwhen mitotic activity ceased 16 . These observations
were interpreted to mean that cdk5 has a role in
neuronal differentiation but not in cell division.
The level of cyclin D1, was similarly observed to
increase during differentiation of diverse cell types.
For example, treatment of three leukemic cell lines
with the differentiation-inducer TPA, led to a marked
increase in cyclin D1 mRNA, to an extensive de-
crease in cyclin E and cyclin A mRNA, and to cell
w xgrowth arrest 42 . Similarly, following treatment of
HL-60 cells with TPA, expression of cyclin D1
mRNA was increased, whereas cyclin A and E ex-
w xpression was markedly inhibited 43 . Cyclin D1
expression was also upregulated in megakaryocytes
w xinduced to differentiate with TPA 44 , and increasing
the level of endogenously or ectopically expressed
cyclin D1 led to inhibition of the growth of normal
w xhuman diploid fibroblasts. 45 . Finally, cyclin D1
expression was enhanced during the neuronal differ-
entiation of PC 12 cells induced by nerve growth
 . w xfactor NGF 46 , and constitutive overexpression of
cdk2 prevented the neuronal differentiation of rat
w xpheochromocytoma PC12 cells 35 . Inversely, the
SV40 large T antigen-mediated immortalization of
human fibroblasts led to a decrease in cyclin D1
expression, accompanied by an increase in the ex-
w xpression of both the cyclins E and A 47 . Thus, in a
variety of cell systems, the expression of cyclin D1,
like that of cdk5, is associated with growth arrest and
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cell differentiation, and it will be of interest to estab-
lish whether in these cells, as they do in ML-1, the
two proteins interact, likely to regulate differentia-
tion-induction.
Our observation that, in nuclear extracts from
growth-stimulated ML-1 cells, cdk2 forms a complex
only with cyclin E, whereas in differentiation-induced
cells cdk5 combines only with cyclin D1, differs
somewhat from results obtained in total extracts from
diverse other cell systems. Thus, in a squamous
carcinoma cell line, cyclin D1 was found to associate
w xwith cdk4 and cdk6 48 , whereas in diploid human
fibroblasts this cyclin coprecipitated with cdk2, cdk4
w xand cdk5 48,49 . Additionally, quarternary com-
plexes were observed to have formed between di-
verse cyclinrcdk combinations and the 21 kDa Cip1
w xand the 36 kDa PCNA proteins 18,49 . It may be
that the formation of some of these complexes in-
volves both the nuclear as well as the cytoplasmic
cell fraction.
Our finding that in control as well as in prolifera-
tion- and differentiation-induced ML-1 cells the D2
and D3 cyclins are expressed relatively early in G1
 .Fig. 6 implies that they participate in events com-
mon to both growth and differentiation, possibly
involving the transit from G0 to G1. As in ML-1
cells, cyclin D2 was expressed earlier than cyclin D3
w xin proliferation-stimulated T-lymphocytes 50 , and in
these -proliferating- cells, cyclin D1 expression was
not detected. Similarly, in proliferating hematopoietic
32D cells, both the D2 and D3 cyclins were ex-
w xpressed, while cyclin D1 expression was absent 51 .
Expression of D2 and D3 cyclins was also induced in
mitogen-stimulated normal lymphocytes and in
MOLT-4 lymphoblastic leukemia cells, where their
w xexpression peaked between 8–24 h 52 .
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